Policy News
2021 Year End Research and Public Health Funding Advocacy Highlights
During 2021, ASH continued to be highly visible in our advocacy for federal support of biomedical research and public health funding, including funding for the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC),...
Read more2021 ASH Advocacy Efforts to Ensure Patient Access to Care
COVID-19 The COVID-19 crisis continues to play a significant role in ASH’s advocacy and practice-related efforts. Below is a list of ASH’s key advocacy and practice-related efforts related to COVID-19. In early March, ASH...
Read more2021 ASH Advocacy Efforts Related to Sickle Cell Disease and Sickle Cell Trait
In 2021, ASH continued to work with federal agencies, leaders at the United States Department of Health and Human Services (HHS) and the U.S. Congress to help enhance and expand government activities in sickle cell disease (SCD) research, training, a...
Read more2021 Year End Physician Payment and Coverage Advocacy Highlights
Medicare Inpatient Hospital Rule ASH offered comments in June on the fiscal year 2022 proposed rule for the Centers for Medicare and Medicaid Services (CMS) Inpatient Prospective Payment System (IPPS). The rule determines payment levels and related...
Read moreASH Summary on the Surprise Billing Interim Final Rule
On July 1, 2021, HHS issued an interim final rule with comment period (IFC) to begin the implementation of the No Surprises Act (NSA) which is the law banning “surprise billing” that was enacted by Congress in December 2020. NSA pro...
Read moreASH Drug Pricing Update
Drug Pricing Debate Heats Up in Congress During the second week in May, two key House Committees held hearings to consider drug pricing legislation. The hearings before the House Energy and Commerce Committee and a subcommittee of the Education and...
Read more2020 ASH Advocacy Efforts to Ensure Patient Access to Care
COVID-19 The COVID-19 crisis dominated much of 2020 and issues surrounding the public health emergency were a main focus of ASH’s advocacy and practice-related efforts. Below is a list of ASH’s key advocacy and practice-related efforts r...
Read more2020 ASH Advocacy Efforts Related to Sickle Cell Disease
In 2020, ASH continued to work with federal agencies, leaders at the United States Department of Health and Human Services (HHS) and the U.S. Congress to help enhance and expand government activities in sickle cell disease (SCD) research, training, a...
Read more2020 Year-End Physician Payment and Coverage Advocacy Highlights
Medicare Inpatient Hospital Rule ASH offered comments on the 2020 proposed rule for the Centers for Medicare and Medicaid Services (CMS) Inpatient Prospective Payment System (IPPS). The rule determines payment levels and related provisions for Medica...
Read more2020 Year-End Research and Public Health Funding Advocacy Highlights
During 2020, ASH continued to be highly visible in our advocacy for federal support of biomedical research and public health funding, including funding for the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CD...
Read more- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9